[Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].

Abstract

Sulphasalazine (SASP) is the drug of choice in the treatment of ulcerative colitis (UC). But there are adverse effects in 20-30% dependent on the serum-level of the resorbed SASP-metabolite sulphapyridine (SP). Relapses during treatment may have their cause in an under-dosage or patient's non-compliance. In 19 patients with UC the possibility of an individualized most effective treatment and the patient's compliance by the simple practicable analysis of SP-serum-level were checked. The results show that it is necessary to dose the SASP in dependence of the genetically determined type of acetylation. The SASP-dosage must be decreased in patients with slow acetylation and vice versa consequently. After rectal SASP-application - in opposite to the oral treatment - significant lower serum levels of SP were analyzed. In 63.1% of the patients we found an insufficient of non-compliance.

• Authors: H J Klugmann, B Giehler, D Lohmann, W Schiedewitz
• Journal: Gastroenterologisches Journal : Organ der Gesellschaft fur Gastroenterologie der DDR (Gastroenterol J) Vol. 49 Issue 4 Pg. 160-4 ( 1990) ISSN: 0863-1743 [Print] Germany
• Vernacular Title: Individuelle Sulfasalazin-Therapie der Colitis ulcerosa und Uberwachung der Patienten-Compliance durch Serumkonzentrationsbestimmung des Sulfapyridin.
• PMID: 1970478 (Publication Type: English Abstract, Journal Article)

Chemical References

• Sulfanilamides
• Suppositories
• Sulfasalazine
• Sulfapyridine

Topics

• Administration, Oral
• Adult
• Aged
• Colitis, Ulcerative (blood, drug therapy)
• Dose-Response Relationship, Drug
• Female
• Humans
• Male
• Middle Aged
• Sulfanilamides (pharmacokinetics)
• Sulfapyridine (pharmacokinetics)
• Sulfasalazine (administration & dosage, adverse effects, pharmacokinetics)
• Suppositories